Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and Low-Intensity Chemotherapy in Ph-Negative Relapsed/Refractory ALL
NCT03518112Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2018
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2018; status: terminated.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03518112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518112.